Time to loading and locoregional control in perioperative high-dose-rate brachytherapy: The tumor bed effect revisited

Martı́nez-Monge, Rafael; Valtueña, G.; Santisteban, Marta; Cambeiro, Mauricio; Arbea, L.; Ramos, Luís; Olarte, A.; San-Julián, Mikel; Alcalde, Juan; Naval-Gías, Luis; Jurado, M.

doi:10.1016/j.brachy.2015.01.006

Cited by 3 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brachytherapy has been shown to be a promising treatment modality in the treatment of recurrent head and neck cancer achieving excellent local control even in the unresectable setting to deliver curative doses [ 18 , 19 , 20 , 21 ]. Unlike EBRT, brachytherapy is able to deliver a high-localized dose with relative sparing of critical normal tissues due to rapid tissue falloff [ 22 ].…”

Section: Purposementioning

confidence: 99%

Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes

Pham

Arora

Wernicke

et al. 2015

jcb

View full text Add to dashboard Cite

PurposeThe feasibility and efficacy of re-irradiation using contemporary radiation techniques to treat recurrent head and neck cancer has been demonstrated but the role of brachytherapy is unclear. Here we describe the use of 131Cs brachytherapy with concurrent salvage surgery in 18 patients.Material and methodsEligible patients underwent maximal gross resection of the tumor with implantation of brachytherapy seeds delivering a minimum dose of 80 Gy to the tumor bed. Rates of overall survival, locoregional progression free survival, disease-free survival, and radiation-induced toxicity were analyzed.ResultsRetrospective Kaplan-Meier analysis shows median overall survival was 15 months and disease free survival was 12 months. Two patients developed grade 3 toxicity; all other complications were grade 1-2 with no grade 4 or 5 complications.ConclusionsCompared to prior literature, our study shows comparable rates of survival with a decreased rate of radiation-induced toxicity.

show abstract

Section: Purposementioning

confidence: 99%

Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes

Pham

Arora

Wernicke

et al. 2015

jcb

View full text Add to dashboard Cite

show abstract

“…Even when brachytherapy is given to the surgical bed, an R1 resection was associated with worse local control than an R0 resection 88 ; a brachytherapy boost should not be used as a substitute for a margin‐negative resection. The timing of brachytherapy (whether before postoperative day five or after) did not seem to have a statistically significant impact on patients with newly diagnosed SCCHN 89 …”

Section: Topic 1: Summary Of Studies With Oncologic Endpointsmentioning

confidence: 85%

“…Studies with primary oncologic endpoints are shown in the Table S1 and included 11 systematic reviews, [20][21][22][23][24][25][26][27][28][29][30] 24 randomized trials with four long-term updates, 19, 29 non-randomized clinical trials, [15][16][17][18] and nine post hoc analyses of randomized trials. [83][84][85][86][87][88][89][90][91] The randomized trials are presented in Table 4. Studies that focused on nononcologic endpoints are shown in the Table S2 and included two systematic reviews, 92,93 one randomized trial, 94 and 21 non-randomized clinical trials.…”

Section: Summary Of Evidencementioning

confidence: 99%

“…Studies with primary oncologic endpoints are shown in the Table S1 and included 11 systematic reviews, 20‐30 24 randomized trials with four long‐term updates, 19,31‐57 29 non‐randomized clinical trials, 15‐18,58‐82 and nine post hoc analyses of randomized trials 83‐91 . The randomized trials are presented in Table 4.…”

Section: Topic 5: Resected P16‐positive (Hpv‐mediated) Squamous Cell mentioning

confidence: 99%

“…The timing of brachytherapy (whether before postoperative day five or after) did not seem to have a statistically significant impact on patients with newly diagnosed SCCHN. 89…”

Section: Port and Other Chemotherapy Regimensmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review of postoperative therapy for resected squamous cell carcinoma of the head and neck: Executive summary of the American Radium Society appropriate use criteria

et al. 2020

View full text Add to dashboard Cite

Background: The aims of this systematic review are to (a) evaluate the current literature on the impact of postoperative therapy for resected squamous cell carcinoma of the head and neck (SCCHN) on oncologic and non-oncologic outcomes and (b) identify the optimal evidence-based postoperative therapy recommendations for commonly encountered clinical scenarios. Methods: An analysis of the medical literature from peer-reviewed journals was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. Prospective studies and methodologybased systematic reviews and meta-analyses of postoperative therapy for SCCHN were identified by searching Medline (OVID) and EMBASE (Elsevier)

show abstract

Braquiterapia adyuvante de alta tasa de dosis en el tratamiento de pacientes con carcinoma de cabeza y cuello: aplicabilidad de los datos dosimétricos

García-Consuegra

View full text Add to dashboard Cite

ADC Coeficiente de Diffusion Aparente AJCC American Joint Committee on Cancer AMV Análisis Multivariante AUV Análisis Univariante AUC Area Under the Curve b.i.d bis in die BRCA Breast Cancer Gene 1 CCND1 Cyclin D1 CTCAE Common Terminology Criteria for Adverse Events CTV Clinical Target Volume DVH Dose Volume Histogram ADN Ácido Desoxirribonucleico EBRT/RTE External Beam Radiation Therapy/Radioterapia externa EGFR Epidermal Growth Factor Receptor ERBB Erythroblastic leukemia viral oncogene homologue EQD2-DVH (EUD) Equivalent Uniform Dose GEC-ESTRO Groupe Européen de Curiethérapie (GEC) and European Society for Radiotherapy & Oncology (ESTRO) ECS Extracapsular spread EQD2 Equivalent Dose 2Gy FDG Fluorodeoxyglucosa Gy Gray GTV Gross Tumor Volume DHI Homogeneity Index HER2 Receptor Tirosina-proteína Quinasa erbB-2 HTA Hipertensión Arterial HDRB High Dose Rate Brachytherapy HR Hazard Ratio

show abstract

Time to loading and locoregional control in perioperative high-dose-rate brachytherapy: The tumor bed effect revisited

Cited by 3 publications

References 14 publications

Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes

Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes

Systematic review of postoperative therapy for resected squamous cell carcinoma of the head and neck: Executive summary of the American Radium Society appropriate use criteria

Braquiterapia adyuvante de alta tasa de dosis en el tratamiento de pacientes con carcinoma de cabeza y cuello: aplicabilidad de los datos dosimétricos

Contact Info

Product

Resources

About